Dexcom, Inc. (NASDAQ:DXCM) is a prominent player in the medical device industry, specializing in continuous glucose monitoring systems for diabetes management. The company has established itself as a leader in this niche market, competing with other medical device manufacturers like Abbott Laboratories and Medtronic. Dexcom's innovative technology aims to improve the quality of life for individuals with diabetes by providing real-time glucose monitoring.

On October 31, 2025, Wells Fargo set a price target of $93 for DXCM, suggesting a potential price increase of approximately 36.36% from its current price of $68.20. This optimistic outlook contrasts with recent market activity, where Dexcom shares experienced a significant decline, dropping 12% in premarket trading. This downturn was triggered by company executives signaling that the growth forecast for 2026 might not meet Wall Street's expectations.

Despite the recent decline, DXCM's current stock price of $68.20 reflects a slight increase of 0.02, or approximately 2.93%. The stock has traded between a low of $68.00 and a high of $69.17 today. Over the past year, DXCM has reached a high of $93.25 and a low of $57.52, indicating some volatility in its stock performance. The company's market capitalization stands at approximately $26.74 billion, highlighting its significant presence in the medical device sector.

Today's trading volume for DXCM is 6.76 million shares, suggesting active investor interest despite recent challenges. As highlighted by the recent price target set by Wells Fargo, there is still optimism about Dexcom's potential for growth. However, the company's ability to meet or exceed growth expectations will be crucial in determining its future stock performance.